Corporate Ethics and Governance  
  Home Guidance Documents Company search File a Report  

Company: Pfizer

Track this Company

Group sues Pfizer, other drug makers over imports

Date Class
19th May 2004 Questionable Business Practice
A Minnesota seniors group sued nine major pharmaceutical manufacturers on Wednesday, alleging that the companies have conspired to keep U.S. medicine prices artificially high by blocking Canadian imports.

Peter Wyckoff, executive director of the Minnesota Senior Federation's metropolitan-region office, said the lawsuit -- which the organization hopes will be awarded class-action status -- represents a new phase in the group's efforts to make it easier to import drugs at lower Canadian prices.

"We have three branches of government that can change things," he said. "This is the third."

The lawsuit in U.S. District Court in Minneapolis alleges that Pfizer Inc., GlaxoSmithKline, Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis and Wyeth Pharmaceuticals have acted in concert to block the supply of name-brand drugs to Canadian pharmacists who sell to U.S. citizens.

In a statement, Pfizer said its practices comply with U.S. law and federal regulations.

"The simple truth is that the importation of pharmaceutical products into the U.S. from Canada is not only illegal, but also dangerous because it increases the opportunity to introduce counterfeit or unapproved pharmaceutical prod-

ucts into the market," said the statement from spokesman Bryant Haskins.

The lawsuit seeks attorneys' fees, unspecified damages and a stop to the companies' anti-import efforts. It's premised on federal antitrust laws as well as specific state consumer-protection laws.




Corporate Ethics and Governance is a service from International Charter
Use of this Service is acceptance of the Terms of Agreement
EU Privacy Shield